A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following conditions are excluded:
• •Intolerance to AZT.
• •Current diagnosis of malignancy for which systemic therapy will be required during the study.
• •Concurrent Medication:
• •Excluded:
• •Any other investigational drugs.
• •Prior Medication:
• •Excluded:
• •Cytotoxic chemotherapy within 1 month prior to study entry.
• •Prior U-87201E or any other non-nucleoside antiretroviral medications, including but not limited to nevirapine, TIBO R-82150 or TIBO R-82913, L-697639 or L-696229, U-90152S, or any protease inhibitors.
• •Antiretroviral agents other than AZT within 3 months prior to study entry.
• •Required:
• •AZT for at least 3 months prior to study entry. Present use of excessive alcohol or illicit drugs.